Hepion Pharmaceuticals
Presencia
Hepion Pharmaceuticals es una empresa que cotiza bajo el símbolo de cotización HEPA (US).
Ejecutivos
Ver el organigrama con sus 12 ejecutivos principales
Biografías más buscadas en Hepion Pharmaceuticals
- John Cavan, Chief Financial Officer and Interim Chief Executive Of...
- Gary Jacob, Chairman of the Board
- John Brancaccio, Director
Recientes movimientos de ejecutivos en Hepion Pharmaceuticals
- Michael Purcell, se ha incorporado a la empresa como Director (noticia publicada el 7 de marzo de 2024).
- Robert Foster, Chief Executive Officer and Director, ha dejado la empresa (noticia publicada el 7 de diciembre de 2023).
- John Cavan que ha sido Chief Financial Officer, ha ascendido a Chief Financial Officer and Interim Chief Executive Officer (noticia publicada el 7 de diciembre de 2023).
Haga clic aquí para ver otros movimientos en Hepion Pharmaceuticals
Crear su alerta
para seguir los movimientos de los ejecutivos en Hepion Pharmaceuticals.
Farmacia
Hepion Pharmaceuticals tiene 1.861 competidores entre los que se incluyen Pfizer (Estados Unidos), Sanofi (Francia) y Johnson & Johnson (Estados Unidos).
Popular M&A news in Farmacia
- MedMen has filed for bankruptcy protection (publicado el 28 de abril de 2024).
- AstraZeneca has announced the acquisition of Fusion Pharma (publicado el 23 de marzo de 2024).
- AstraZeneca has announced the acquisition of Amolyt Pharma (publicado el 19 de marzo de 2024).
Otros contactos sugeridos en el sector Farmacia
Noticias
Últimos comunicados de prensa de Hepion Pharmaceuticals
- Hepion Pharmaceuticals Initiates Wind-Down Activities in Phase 2b ‘ASCEND-NASH’ Trial – Hepion Pharmaceuticals
- Hepion Pharmaceuticals Strengthens Board of Directors with Appointment of Michael Purcell – Hepion Pharmaceuticals
- Hepion Pharmaceuticals Announces Exercise of Warrants for Approximately $2.0 Million Aggregate Gross Proceeds – Hepion Pharmaceuticals
- Hepion Pharmaceuticals to Present at NASH-TAG 2024 – Hepion Pharmaceuticals
- Hepion Pharmaceuticals Announces Restructuring Plan to Enhance Shareholder Value and Management Changes – Hepion Pharmaceuticals
- Hepion Pharmaceuticals to Present at the 7th Obesity & NASH Drug Development Summit – Hepion Pharmaceuticals
- Hepion Pharmaceuticals Schedules Conference Call to Review Additional Efficacy Data from Phase 2 ‘ALTITUDE-NASH’ Liver Function Trial of Rencofilstat – Hepion Pharmaceuticals
- Hepion Pharmaceuticals’ Rencofilstat Demonstrates Anti-Cancer Activity in Hepatitis C-Associated Cancer Model – Hepion Pharmaceuticals
- Hepion Pharmaceuticals to Participate in 2023 Cantor Global Healthcare Conference – Hepion Pharmaceuticals
- Hepion Pharmaceuticals Discovers Novel Rencofilstat Action in Liver Cancer – Hepion Pharmaceuticals
- View more press releases Close
Redes sociales sobre Hepion Pharmaceuticals
- Hepion Pharmaceuticals en Wikipedia, Google News y Yahoo Finance
- Hepion Pharmaceuticals en LinkedIn, Twitter y YouTube
Ponerse en contacto
Contactar a través de e-mail con sus ejecutivos John Cavan 
Llame a Hepion Pharmaceuticals al +1 212...
